USA flag logo/image

An Official Website of the United States Government

Engineered proteins from transgenic animals

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R44GM090626
Solicitation Year:
2012
Solicitation Topic Code:
NIGMS
Solicitation Number:
PA11-096
Small Business Information
CRYSTAL BIOSCIENCE, INC.
5980 Horton Street Suite 405 EMERYVILLE, CA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2012
Title: Engineered proteins from transgenic animals
Agency: HHS
Contract: 2R44GM090626-02A1
Award Amount: $1,805,815.00
 

Abstract:

DESCRIPTION (provided by applicant): Approximately 25% of the products being developed by the biotechnology industry are antibodies and many of these antibodies are directed to epitopes on human cells and tissues. We are proposing a novel concept for the production of antibodies with therapeutic potential that is based on recent advances in protein-protein interactions and recent developments in transgenic technology. Execution of this concept will obviate many of the expensive and time consuming modifications that are frequently required after potentially therapeutic monoclonal antibodies are identified in order to optimize their pharmacological properties and to make them amenable to large scale production. By combining recent data derived from in vitro studies with the nascent understanding of genomics, we will extend the range of epitopes that can be accessed and, therefore, extend the range of potentially therapeutic antibodies. PUBLIC HEALTH RELEVANCE: During the past 15 years, more than 20 therapeutic antibodies have been developed to treat human disease, particularly in the fields of autoimmunity and cancer. We have proposed a novel method to obtain potentially therapeutic antibodies that will recognize targets that cannot be obtained from conventional sources. In addition, the technology will engineer antibodies that have improved pharmacological attributes and better manufacturing properties. This technology will provide a cost-effective route to increasing the range of therapeutic candidatesfor the treatment of human disease.

Principal Investigator:

Philip Leighton
510-768-7758
pal@crystalbioscience.com

Business Contact:

Philip Leighton
510-768-7758
pal@crystalbioscience.com
Small Business Information at Submission:

CRYSTAL BIOSCIENCE, INC.
5980 Horton Street Suite 405 EMERYVILLE, CA -

EIN/Tax ID: 126285116
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No